

ANCON Medical presents to clinical experts in Lung Cancer

ANCON is proud to be invited to present at ADVANCING EARLY DETECTION OF LUNG CANCER in association with the Cleveland Clinic in Ohio

BLOOMINGTON, MINNESOTA, UNITED STATES, April 25, 2018 /EINPresswire.com/ -- The meeting brings together industry partners committed to performing excellent science in the pursuit of meaningful clinical advances in early detection of lung cancer. The conference invites clinical experts to share their perspective on what the needs of lung cancer detection are, and industry researchers to share their achievements and thoughts about the future.

Representing ANCON Medical, Dr Glyn Hiatt-Gipson PhD leads a discussion on molecular biomarker detection in screening and early-stage diagnostic. Lung cancer is precisely the kind of disease where ANCON Medical's advanced disease screening technology can be life-saving. Non-invasive, simple to use, and affordable, the ANCON's Nanoparticle Biomarker Tagging (NBT) technology can detect the presence of disease by measuring exhaled breath for signs of the disease.



3D illustration of Lungs

The technology works by detecting breath specific “biomarkers,” which are DNA-protein controlled volatile organic compound (VOC) metabolites specific to diseases. Researchers have discovered biomarkers for more than 400 diseases, including lung and other cancers.

“

The NBT device is very versatile. It can be used to screen for diseases such as cancer and later be reassigned to test for a range of other diseases when needed”

Wesley Baker - CEO of Ancon Medical

By using machine learning software in association with the NBT technology the device can hunt for these specific molecules, so that the disease can be diagnosed early, thereby increasing treatment options and survival probability. No technology on the market is as highly sensitive at detecting biomarkers as NBT, which can detect the fingerprints of the disease at concentrations as low as one ion in 10,000 cubic centimeters, giving the device a sensitivity that could be measured down to a single molecule.

Alongside Dr Hiatt-Gipson's presentation, the forum promotes collaboration between clinical experts

and industry researchers, and between companies with similar goals and needs. Other discussion topics include; imaging advances, biopsy technology development, population management tools, and lung cancer advocacy.

“The NBT device is very versatile. It can be used to screen for diseases such as cancer and later be reassigned to test for a range of other diseases when needed,” says ANCON Medical’s CEO, [Wesley Baker](#), who is a member of the Royal Society of Medicine. “Lung cancer, scleroderma, cervical cancer, the Flu virus, tuberculosis and chronic obstructive pulmonary disease (COPD) are just some of the diseases where known biomarkers have been discovered, and ANCON’s NBT can improve the speed of diagnosis.”

For more information on Ancon Medical’s NBT technology research, visit ANCON’s website by [clicking here](#).


Further information:

Meeting organizer, Dr Peter Mazonne MD, MPH, is Director of the Lung Cancer Program and Lung Cancer Screening Program for the Respiratory Institute, [Cleveland Clinic](#) and is a world leader when it comes to Lung Cancer. Board-certified in internal medicine, pulmonary medicine and critical care medicine, Dr Mazonne’s research surrounds include cancer biomarker development (breath analysis, blood and urine testing), lung cancer diagnostics, lung nodule evaluation, lung physiology assessment and lung cancer screening.

Joanna Stephens
Ancon Technologies & Ancon Medical
+44 1227 811705
email us here



Lung cancer human body



Young Cancer Patient

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.